Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis

医学 科克伦图书馆 内科学 不利影响 入射(几何) 荟萃分析 系统回顾 肿瘤科 肺癌 梅德林 政治学 光学 物理 法学
作者
Huijun Xu,Yang Yang,Ying Yan,Mengge Li,Shusheng Wu,Lulu Cao,Wenju Chen,Huiqin Luo,Yifu He
出处
期刊:Cancer Medicine [Wiley]
卷期号:13 (20)
标识
DOI:10.1002/cam4.70324
摘要

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have drastically shifted the current landscape toward a wide variety of malignancies. However, ICIs are interrupted owing immune‐related adverse events (irAEs), therapy completion, and disease progression. The risk–benefit of rechallenged ICIs remains inconclusive. Herein, a systematic review and meta‐analysis were conducted to evaluate the safety and efficacy of ICI rechallenge in the treatment of advanced solid tumor. Methods PubMed, Web of Science, Embase, and Cochrane Library were searched to analyze the efficacy and safety of ICI rechallenge. The study protocol was approved by the PROSPERO International Register of Systematic Reviews (CRD42022372222). The last updated search date was March 2, 2024. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence rates of all‐ and high‐grade irAEs were evaluated. Results A total of 41 retrospective studies comprising 2343 patients were ultimately enrolled for qualitative and quantitative assessments. A total of 1200 (51.2%) individuals were male and the median age was 66 years (range 18–97 years). The majority of the tumors was lung cancer ( n = 898, 38.3%). The occurrence rates of all‐grade and high‐grade (grade 3 or 4) irAEs between initial and readministration ICIs were not significantly different (all‐grade: OR, 0.75, 95% CI: 0.39–1.45, p = 0.40; I 2 = 87%; high‐grade: OR, 0.96, 95% CI: 0.62–1.49, p = 0.87, I 2 = 65%). ICIs restart presented a decreased ORR and DCR compared to initial ICI administration (ORR: OR, 0.36, 95% CI: 0.23–0.56, p < 0.00001; I 2 = 67%; DCR: OR, 0.62, 95% CI: 0.43–0.89, p = 0.010; I 2 = 53%). Seven studies with 513 patients for survival analysis revealed a nonsignificant difference in OS between the ICIs rechallenge and discontinuation cohorts (hazard ratio [HR]: 0.68, 95% confidence interval (CI): 0.35 to 1.35, p = 0.27). Conclusion Rechallenging immunotherapy is feasible, and patients should be carefully evaluated by a multidisciplinary team prior to initial therapy for close monitoring and assessment of the risk–benefit ratio. Therefore, prospective trials are essential to guide clinicians in the decision‐making process. PROSPERO Registration: CRD42022372222.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
a雪橙完成签到 ,获得积分10
1秒前
超帅的碱完成签到,获得积分10
1秒前
2秒前
陈大海完成签到,获得积分20
2秒前
LaTeXer给积极行天的求助进行了留言
2秒前
白斯特完成签到,获得积分10
3秒前
科研混子完成签到,获得积分10
3秒前
听雨完成签到 ,获得积分10
3秒前
jianglili完成签到 ,获得积分10
3秒前
思源应助王云骢采纳,获得10
4秒前
等待的航空完成签到 ,获得积分10
5秒前
顾矜应助乔安采纳,获得10
5秒前
雪ノ下詩乃完成签到,获得积分10
6秒前
神外之城发布了新的文献求助80
6秒前
科研人完成签到,获得积分10
8秒前
莫友安完成签到 ,获得积分10
8秒前
大个应助迅速曼冬采纳,获得10
9秒前
热心市民小红花应助阿湫采纳,获得10
10秒前
快乐战神没烦恼完成签到,获得积分10
10秒前
顾矜应助魏莱采纳,获得10
10秒前
SYLH应助Rollei采纳,获得10
10秒前
11秒前
dd完成签到,获得积分20
11秒前
刻苦羽毛完成签到,获得积分10
12秒前
小粒橙完成签到 ,获得积分10
13秒前
lulu完成签到,获得积分10
16秒前
凤里完成签到 ,获得积分10
16秒前
星辰大海应助虹虹采纳,获得10
16秒前
19秒前
19秒前
cassie完成签到,获得积分10
19秒前
兴奋的乐巧完成签到,获得积分10
20秒前
jia完成签到,获得积分10
22秒前
马某关注了科研通微信公众号
22秒前
完美诺言发布了新的文献求助10
22秒前
22秒前
Jonathan完成签到,获得积分10
23秒前
zkkz完成签到,获得积分10
23秒前
drzz发布了新的文献求助10
24秒前
喜悦的板凳完成签到 ,获得积分10
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048